Premium
MUCOSAL PROTECTIVE AGENTS PREVENT EXACERBATION OF NSAID‐INDUCED SMALL INTESTINAL LESIONS CAUSED BY ANTISECRETORY DRUGS IN RATS
Author(s) -
Satoh Hiroshi,
Amagase Kikuko,
Yokoi Ami,
Ohashi Masato,
Kuwata Sayumi,
Mochizuki Sari,
Takeuchi Koji
Publication year - 2013
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.27.1_supplement.1093.10
Subject(s) - ranitidine , medicine , pharmacology , exacerbation , omeprazole , misoprostol , histamine , histamine h2 receptor , mucosal lesions , gastroenterology , antagonist , receptor , pregnancy , abortion , biology , genetics
Non‐steroidal anti‐inflammatory drugs (NSAIDs) have been reported to be a common cause of small intestinal lesions in humans; however, there are few effective agents for the treatment of this complication. Antisecretory drugs such as histamine H2‐ receptor antagonists and proton pump inhibitors are commonly used for the treatment of upper gastrointestinal mucosal lesions induced by NSAIDs. However, it has recently been reported that these drugs aggravate NSAID‐induced small intestinal lesions in rats. We examined the effect of mucosal protective agents (MPA) on the exacerbation of NSAID‐induced intestinal lesions caused by ranitidine (RAN) or omeprazole (OPZ). Male Wistar rats (180–220g) were used. Both RAN (30 mg/kg) and OPZ (100) significantly increased the intestinal lesions induced by low doses of DIC (3 and 6). All of misoprostol (0.03–0.3), irsogladine (1–10) and rebamipide (10–300) prevented the increase of lesions dose‐dependently. These results indicate that: 1) antisecretory drugs enhance the potential ulcerogenic effect of low (clinical) doses of NSAIDs; and 2) MPAs prevent the exacerbation of NSAID‐induced intestinal lesions caused by antisecretory drugs.